 |
Pradaxa®
We are currently investigating and evaluating bleeding injuries associated with the use of Pradaxa®, an anti-clotting medication approved to prevent the formation of blood clots in patients with atrial fibrillation not caused by cardiac valve deficiencies. Atrial fibrillation, or A-Fib, as it is commonly known, occurs when the atrial chambers of the heart (the smaller, upper chambers) beat in an irregular fashion so that they are rhythmically out of sync with the lower, larger chambers of the heart – the ventricles. A-Fib can be caused by numerous conditions.
Pradaxa® is an anti-blood-clotting drug that was approved in October 2010 by the FDA for treatment of patients with A-Fib not caused by cardiac valve deficiencies. Since its introduction in the US, there have been numerous reports of bleeding injuries, most notably hemorrhages, associated with the use of Pradaxa®.
If you or a loved one suffered a hemorrhage or other bleeding injury while taking Pradaxa®, we would like to speak with you. Please send us your contact information and we will contact you within 24 hours or fill out our E-CONTACT Form.
DISCLAIMER
|
|
 |
|
 |
 
|
If you or a loved one suffered a hemorrhage or other bleeding injury while taking Pradaxa®, we would like to speak with you. Please send us your contact information and we will contact you within 24 hours or fill out our
E-CONTACT Form.
We will contact you promptly - in all events, within 24 hours.
|
|
|
|
